Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of JLP-2008 vs Co-administration of JT-001 and JT-002 in Healthy Subjects
NCT06165965Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JLP-2008 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve over 24 hours and Maximum Plasma Concentration at 24 hours. Started May 2022; status: completed.
02
Drugs
JLP-2008
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06165965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06165965.